FDA Pre-Emption Wins On Appeal
This article was originally published in The Tan Sheet
Executive Summary
Lawsuits brought against GlaxoSmithKline and Pfizer over "failure to warn" claims for their antidepressant drugs are pre-empted by FDA's authority over labeling, the Third Circuit U.S. Court of Appeals has ruled. But industry's liability risks will likely be determined more by an upcoming Supreme Court case
You may also be interested in...
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation